Talis Biomedical Corporation

OTCPK:TLIS Stock Report

Market Cap: US$3.1m

Talis Biomedical Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:TLIS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Sep 24BuyUS$44,240BML Capital Management, LLCCompany30,100US$1.48
03 Sep 24BuyUS$2,000BML Capital Management, LLCCompany500US$4.00
30 Aug 24BuyUS$642BML Capital Management, LLCCompany151US$4.25
28 Aug 24BuyUS$56,137BML Capital Management, LLCCompany14,382US$3.96

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TLIS?
Owner TypeNumber of SharesOwnership Percentage
Private Companies480.00263%
Institutions1900.0104%
Individual Insiders151,5828.32%
Hedge Funds757,02541.5%
General Public913,97550.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 14 shareholders own 49.86% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
27.9%
Baker Bros. Advisors LP
508,323US$864.1k0%0.01%
13.6%
BML Capital Management, LLC
248,702US$422.8k482%0.25%
6.3%
Randal Scott
114,884US$195.3k0%no data
0.97%
Rustem Ismagilov
17,712US$30.1k0%no data
0.76%
Kimberly Popovits
13,855US$23.6k0%no data
0.23%
Matthew Posard
4,167US$7.1k0%no data
0.037%
Robert Kelley
683US$1.2k0%no data
0.015%
Heinrich Dreismann
274US$465.70%no data
0.0081%
Steward Partners Investment Advisory, LLC
147US$249.80%no data
0.0022%
FBB Associates
40US$67.90%no data
0.0021%
Securities America Advisors, Inc.
38US$64.50%no data
0.00044%
FBB3 LLC
8US$13.60%no data
0.00038%
Melissa Gilliam
7US$11.80%no data
0.00027%
Guggenheim Partners, LLC
5US$8.40%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 16:23
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Talis Biomedical Corporation is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Derik de BruinBofA Global Research
Mark MassaroBTIG
Tycho PetersonJ.P. Morgan